Terlipressin Hrs denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Cite "Not FDA-Approved" for Terlipressin — and How to Respond

Terlipressin has received FDA approval for hepatorenal syndrome type 1 (HRS-1). A "not FDA-approved" denial from Humana is therefore either a policy-lag error (Humana's coverage criteria have not been updated since the approval) or a reviewer error (the denial was issued against an outdated policy or against an assumption of off-label use). In either case, this is one of the most directly rebuttable denial types.

### Why This Denial Happens

Insurer coverage policies are updated on a cycle, and FDA approvals — particularly for specialty or rare-disease drugs — sometimes outpace policy revisions. A reviewer applying a legacy policy template may issue a "not approved" denial without recognizing that approval was subsequently granted. This denial may also arise if the claim was submitted with a code combination that the system did not associate with the FDA-approved indication.

### Why It's Appealable

FDA approval is a matter of public record. An independent external reviewer applying the ACA §2719 external-review framework will have access to the current FDA labeling and will weigh it. Under ERISA §503, the plan must provide a full-and-fair review that considers all clinical evidence, including the prescribing label. File for external review within approximately four months of the denial notice; request expedited review (72-hour turnaround) if the patient's condition is urgent.

### Concrete Appeal Process

1. Attach the FDA prescribing label — Download the current labeling from the FDA's DailyMed database and include it as Exhibit A in your appeal packet. 2. Request Humana's policy and its effective date — Compare the policy date to the FDA approval date; if the policy predates approval, state this explicitly in your appeal letter. 3. Internal appeal — File within the deadline shown on the denial letter, leading with the FDA approval documentation. 4. External review — File immediately after an internal denial; external reviewers are not bound by Humana's internal policy and will apply the FDA label directly.

### Documentation to Gather

• FDA approval documentation — current prescribing information from DailyMed confirming approval status and the specific approved indication for HRS-1.
• Diagnosis confirmation — hepatologist or intensivist chart notes establishing an HRS-1 diagnosis consistent with the labeled indication.
• Clinical context — chart documentation of the acuity, treatment setting, and urgency of the patient's condition.
• Prescriber medical-necessity letter — the treating physician should confirm the use is within the FDA-approved indication and consistent with current professional society guidance (such as AASLD guidance on HRS).

### Criteria-Mapping Structure

Your appeal letter should address the denial basis directly and narrowly: state the date terlipressin received FDA approval, cite the approved indication, confirm that the requested use falls within that indication, and reference the current prescribing label attached as an exhibit. Then provide the diagnosis documentation showing the patient meets the labeled indication. This focused rebuttal — approval documentation plus diagnosis match — is the complete argument for reversing a not-FDA-approved denial for an on-label use.